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ASP per therapy. RESULTS: Annual net reimbursement revenues per patient based 
on 340B acquisition costs were projected to be $53,270 for dabrafenib+trametinib 
combination, $27,043 for vemurafenib, $22,634 for dabrafenib, and $19,029 for 
trametinib. CONCLUSIONS: The addition of user-modifiable projected reimburse-
ment revenue calculation is a valuable tool that expands the contribution of eco-
nomic modeling to hospital formulary decision-making.
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OBJECTIVES: Strategies for screening incident colorectal cancers(CRC) for possible 
Lynch syndrome(LS) are evolving rapidly. Our objective is to compare the diagnos-
tic results and costs from two strategies for LS screening: Targeted Screening(TS) 
and Universal Screening(US) of tumors for mismatch repair(MMR) abnormali-
ties. METHODS: For 18-months in 2010-2011, we employed TS - individuals under 
60 years old and those meeting Bethesda criteria for LS. In 2012, we began US of all 
CRC. Immuno-histochemical(IHC) staining for the four MMR proteins was done in all 
cases. Microsatellite instability, BRAF mutation, MLH1 promoter methylation testing, 
and/or genetic testing of germ line DNA were done in selected cases. We modeled 
the diagnostic costs of several strategies for detecting LS, and the downstream costs 
of prevention CRC through colonoscopy screening, using a system dynamics model, 
built in the “Anylogic” program. RESULTS: In 2010-2011, 51 of 175 (29%) incident 
CRCs were screened by IHC using TS strategy; 15(29%) showed abnormal loss of 
> 1 MMR protein. Germ line MMR gene mutations were found in 4 cases and were 
suspected but not demonstrated in 11 additional cases. In 2012-2013, 194 CRCs were 
screened by IHC using US; 13(6.7%) of CRCs had abnormal staining suspicious for 
LS. MMR mutations were found in only 2/9 cases abnormal for IHC. Cost to identify 
the LS probands was ~$8,339/LS case diagnosed for targeted screening (four muta-
tion carriers/18 months) and ~$32,708/LS case diagnosed for universal screening 
(two mutation carriers/24 months). CONCLUSIONS: Real-world results were more 
complicated than anticipated. Results from US with IHC were often atypical, not 
diagnostic of LS. Economic analysis using our costs suggests that TS is less costly 
than US, but it will miss some cases of mildly penetrant LS. US identifies changes 
that are currently of unknown significance but that have potential to contribute to 
future research into the mechanisms of CRC tumorigenesis.
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OBJECTIVES: Little is known about cancer (CA) in hospitalization, cost and out-
comes in transitional countries. We studied this in a multicentric hospital study 
in Argentina. METHODS: Adult CA, hospital direct costs, re-admissions (ReH < 30 
days) and deaths in 1 yr output of 3 academic hospitals. Cost and results, harmo-
nized according HCUPS (USA) terminology groupers, of primary (1Dx), and second-
ary diagnosis (2Dx) for each CCS code (Clinical Classification Software-CCS single 
level-SL, 2009). Total costs (CT$), mean costs (SD) and median per discharge cost 
($, 25P-75P-percentiles), in Itl.$ PPP, (UN Data: 1Arg$ = 1.608 PPP, 2008). CA defined 
as (#CCS [descriptive term]), including from CCS #11 [head and neck CA] to #44 
[Neoplasms of unspecified nature or uncertain behavior] and CCS 45 [Maintenance 
chemotherapy; radiotherapy--QT;RT]. Readmisions (ReH) < 30 days and hospital 
deaths were obtained. RESULTS: Among 45 466 ≥ 19 yrs.old, CA was found in 6 
282, 13,81%(95%CI 13,50-14,14) Dx1; CCS 11-45 (F= 49,33%) (individual CA data not 
shown) while QT;RT (# 45) = 2 520 disch., 5,54% (4,75-5,15). Among CCS 45 [QT;RT] en 
1Dx, CCS #11-44 in any 2Dx up to 5 2Dx code adds 3,046 disch; adding CA codes 1Dx 
+2Dx = 9.298 discharges (20,45%, 20,08-20,82). Among CCS en 1Dx, CT $ = I $ PPP 64 
088 727; mean: I$ 17,035; SD: I$ 4,276; median: I$ 8,897 (25P 4,042; 75 P 19,601). ReH 
< 30 d = 485 (1,06 %, 0.97-1,16); while QT-RT (#45) ReH< 30 = 1,754 (3,86%, 3,68-4,04). 
Case fatality rate for CCS 11-44 was 3,27%,(2,86-3,74), and for CCS 45 was 0,17%,( 
0,06-0,45). CONCLUSIONS: CA burden among hospital discharges, and its costs, case 
fatality, and readmisions were obtained for the first time in Argentina. QT-RT as a 
first Dx is close to half of discharges, and showing CA en 2Dx behaves differently in 
ReH and mortality. An iceberg phenomenon of CA in 2Dx emerges.
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OBJECTIVES: Real-world data may inform decisions regarding treatment for renal 
cell carcinoma (RCC). We compared treatment persistence and healthcare costs for 
sunitinib and pazopanib, considering dosing cycle differences’ effect on days sup-
ply. METHODS: This retrospective cohort study used the Truven Marketscan® data-
base. Inclusion criteria were RCC diagnoses, age ≥ 20 years, ≥ 1 (index) prescription 
for sunitinib or pazopanib 10/1/2009 – 9/30/2013, and continuous plan enrollment ≥ 6 
months before to 12 months after index. We compared demographic and clinical char-
acteristics and treatment patterns, using Chi-square, Student t-test, and Wilcoxon 
signed-rank test (α = 0.05). Costs were compared using generalized linear modeling 
to adjust for demographic, clinical, and medication variables. Sensitivity analysis 
assessed effects of imputing days supply for sunitinib’s 42-day dosing for prescrip-
tions with 28 or 30 days supply. RESULTS: Among 466 patients (77% receiving suni-
tinib), the cohorts were not significantly (NS) different in demographics or Charlson 
Comorbidity Index. More sunitinib patients (46 vs. 6 pazopanib patients; p= 0.038) had 
of public healthcare in Ecuador to predict the financial consequences of introducing 
axitinib as a second line treatment in Ecuador. METHODS: Using a budget Impact 
analysis model, we estimated the incremental impact in the Ministry of public 
healthcare budget in Ecuador with the introduction of axitinib as treatment for 
mRCC in whom have failed the first line treatment. The comparative used drugs 
were sorafenib, everolimus, sunitinib, pazopanib and bevacizumab + IFNa. The epi-
demiological data was taken from GLOBOCAN 2012. The costs information 2014 was 
obtained from public sources and the model was built in Microsoft Excel 2007. The 
economic analysis is based in the incidence of RCC: metastatic, non-metastatic 
and the percentage of the patients with progression. The model considers two sce-
narios: 1) The current market of treatment without Axitinib, 2) The current market 
adding Axitinib. RESULTS: Based on the incidence of RCC and the Ecuador popula-
tion, we calculated 269 incident cases of RCC, 211 with metastatic disease and 58 
who will progress to metastatic disease, 97 patients received a first line treatment 
of whom 40.91% (40 patients) needed a 2ndline treatment. Along a 3 year follow-
up in the scenario were axitinib was added, the estimated cost was $5,810,416.84 
USD, with an incremental change of $26,098.99 USD and an incremental cost for 
the population with access to the national healthcare system of $0.00010 USD p/
month. CONCLUSIONS: The addition of axitinib as a second line treatment for 
mRCC had a minimal impact on the budget designated to the Ministry of public 
healthcare in Ecuador, and since it has an A1 recommendation level, it will represent 
an improvement in the mRCC treatment options.
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OBJECTIVES: Prostate cancer is the second leading cause of cancer death in 
American men and has a high economic burden. Enzalutamide received FDA 
approval for an expanded indication based on significant improvement in overall 
survival and radiographic progression-free survival in chemotherapy-naïve meta-
static castration-resistant prostate cancer (mCRPC) patients. Our objective was to 
estimate the 1-year budget impact (BI) of adopting enzalutamide’s expanded indica-
tion. METHODS: Epidemiologic data, including SEER incidence rates, were used to 
estimate total number of chemotherapy-naïve mCRPC patients in a hypothetical 
1-million member U.S. health plan. Treatment options included abiraterone acetate, 
sipuleucel-T, radium-223 dichloride, and docetaxel. Dosing, administration, mean 
duration of therapy and adverse event (AE) rates were based on package inserts 
and pivotal studies. Drug costs (including pre- and concomitant medications) were 
obtained from RedBook and CMS ASP pricing files, administration and monitoring 
from CMS Physician Fee Schedule, and AEs from AHRQ H-CUP and published litera-
ture. Drug utilization was estimated for each comparator before and after adoption 
of enzalutamide. Incremental aggregate budget, per patient per year (PPPY), per 
patient per month (PPPM), and per member per month (PMPM) impact were cal-
culated. One-way sensitivity analyses were performed. RESULTS: In an estimated 
population of 115 mCRPC patients, adopting the new enzalutamide indication 
had modest annual plan impact ($510,641 incremental aggregate BI, $4,426 PPPY, 
$368.83 PPPM and $0.04 PMPM). Enzalutamide acquisition cost was partially offset 
by moderate AEs and no additional monitoring costs. Results were most sensitive 
to enzalutamide drug cost, size of chemotherapy-naïve mCRPC patient population 
and enzalutamide adoption rate. CONCLUSIONS: Results indicate a modest 1-year 
BI to adopt enzalutamide for chemotherapy-naïve mCRPC patients, partly due to the 
cost offset of moderate incidence of AEs and lack of additional required monitoring. 
Further analysis to understand cost per clinical outcome may complement the BI 
model to understand relative costs and benefits.
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OBJECTIVES: Economic modeling is an accepted tool for making formulary decisions 
by payers in the US. Hospital and institutional healthcare providers have expressed 
increased interest in using economic modeling in their decision making processes, 
particularly regarding potential reimbursement based on hospital-specific pricing. 
This study presents hospital perspective results from a revenue impact (RI) calcula-
tor component of an economic model. METHODS: An economic model was devel-
oped that investigated the RI (pharmaceutical acquisition costs minus projected 
reimbursement) of introducing National Comprehensive Cancer Network Category 1 
recommended therapies for BRAF V600 mutated metastatic melanoma to a hospital 
formulary. Therapies investigated in the analysis included: dabrafenib+trametinib 
combination therapy, vemurafenib monotherapy, dabrafenib monotherapy, and 
trametinib monotherapy. The model calculated the annual pharmaceutical acqui-
sition cost of each therapy based on recommended dosing, progression-free survival 
as a marker for duration of treatment, and drug pricing. Pricing data was retrieved 
from the Truven Health Analytics RED BOOK™ database. Acquisition costs in the 
model could be set to 340B, wholesale acquisition cost (WAC), or average wholesale 
price (AWP) values. The model used a default 30% discount compared to WAC to 
approximate 340B pricing. The projected reimbursement in the model uses WAC 
plus a modifiable 4.3% (based on the Medicare permitted reimbursement premium) 
for both Medicare and commercial payers. The perspective payer mix and respec-
tive reimbursement percentages can be modified by the model user. WAC was used 
in place of average sales price (ASP) due to the unavailability of hospital-specific 
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OBJECTIVES: To examine and compare costs and cost drivers for various meta-
static renal cell carcinoma (mRCC) drugs. METHODS: This retrospective cohort 
study used administrative healthcare claims from MarketScan® Commercial 
and Medicare Supplemental Databases to identify patients newly diagnosed 
with mRCC (index event) from 1/1/2006 to 3/31/2014, with continuous health 
plan enrollment at least 6 months prior to and 30 days following the index 
date. Treatment with approved mRCC products on or after the index date was 
required. Patients were followed until death, health plan enrollment end, ini-
tiation of non-mRCC chemotherapy, or study end. Healthcare costs reflect paid 
amounts to providers and out-of-pocket costs to patients. Bootstrapping was used 
to determine differences between costs of drugs. RESULTS: The study population 
included 3060 mRCC patients. Total per-patient-per-month costs for pazopanib 
($14,486) and sorafenib ($13,841) were not statistically lower at an alpha level of 
0.05 than sunitinib ($15,808). However, temsirolimus ($19,431) and IL-2 ($96,619) 
were significantly more costly than sunitinib. For inpatient and patient out-of-
pocket costs, IL-2 was significantly more costly than sunitinib. Outpatient costs 
of pazopanib and temsirolimus were both significantly more costly than suni-
tinib while sorafenib was significantly less costly. Multivariate modeling found 
that year of index date, number of metastatic sites, NCI comorbidity index score, 
and evidence of an adverse event during first line treatment were significantly 
associated with greater costs for all patients. In general, approximately 46% of 
total costs were specific to mRCC drug costs while 30% were due to inpatient 
stay. CONCLUSIONS: This study demonstrates that there may be significant cost 
differences between mRCC drugs and that mRCC drug costs represent the largest 
driver of total healthcare costs in this patient population. Further research on 
comparative effectiveness, weighing costs relative to clinical benefit, is needed.
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OBJECTIVES: Colorectal cancer (CRC) is a major cause of morbidity and mortality 
worldwide. Approximately 25% of patients present metastatic disease at diagnosis 
and about 50% will develop metastatic disease. Patients with metastatic colorectal 
cancer (mCRC) and wild-type or mutated KRAS are eligible for sequential treat-
ments, including monoclonal antibodies as first or second-line regimens. Use of 
bevacizumab (Bev) through multiple lines (TML) may benefit patients with mCRC. 
Considering the emerging data, it is important to understand these implications 
in terms of costs for the Brazilian private healthcare system. Our objectives were 
to compare economic outcomes of different sequences of therapy including 
monoclonal antibodies for the treatment of mCRC. METHODS: Eight scenarios 
were analyzed, each one comparing different treatment sequences. A sequence 
of bevacizumab TML (first-line and beyond first progression) was compared in 
each scenario with another sequence without bevacizumab TML. To compare 
the economic outcomes, the monthly cost and the total cost of the sequence per 
patient were calculated, according to the first, second and third-lines combina-
tions. RESULTS: Considering a standard time of treatment of 12.8 months and 
progression-free survival (PFS) varying from 17.0 to 20.6, all scenarios with bevaci-
zumab TML were less costly than multiple lines without bevacizumab. The lowest 
monthly cost was related to bevacizumab TML (1stline bevacizumab 5mg+FOLFOX 
→ 2ndline bevacizumab 5mg+FOLFIRI → 3rdline best supportive care [BSC]). This 
sequence represents a monthly cost of R$ 18,192.41 per patient while the same 
scenario with cetuximab in first-line (1stline cetuximab 250mg+FOLFIRI → 2ndline 
bevacizumab 10mg+FOLFOX → 3rdline BSC) represents R$ 23,640.57 per month/
patient. CONCLUSIONS: Use of bevacizumab TML for mCRC is less costly compared 
with sequences of biological therapy that starts with cetuximab in the first-line fol-
lowed by bevacizumab in second-line treatment. Resource savings with sequential 
bevacizumab have the potential to optimize third-line treatment strategy for mCRC 
patients with wild-type KRAS in Brazil.
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OBJECTIVES: To investigate patterns of hemostat methods in surgeries and 
evaluate the healthcare resource utilization and economic burden of patients in 
China. METHODS: All Patients using oxidized regenerated cellulose (ORC), microfi-
brillar collagen hemostat (MCH), resorbable oxidized cellulose (ROC), and micropo-
rous polysaccharide hemispheres (MPH) after cholecystectomy, hysterectomy or 
other related surgeries in tertiary hospitals were identified from the 2012 dataset 
of the China Health Insurance Research Association (CHIRA) claims database which 
includes a nationwide, cross-sectional sampling of inpatients. Direct medical costs 
included diagnostic tests, surgery, physiotherapy, hemostat, medicines and consum-
ables cost. Descriptive statistics were used to describe patient profiles, healthcare 
resource utilization and direct medical cost. Two-tailed tests were performed at 95% 
confidence. Multiple linear regression (MLR) was used to identify main parameters 
that may influence inpatient costs thus providing patient selection criteria for a 
relative unbiased comparison. RESULTS: A total of 788 patients with the following 
characteristics, age, gender, surgery types, hemostats types, Length of Stay (LOS), 
Hospital tier were identified. Factors significantly impacted inpatient cost were 
Length of Stay, type of hemostat (ORC vs. others), tier of Medical Institute (MLR, 
p< 0.01). Among 382 patients who stayed at Tier 3 hospitals with LOS ≤ 14 days, the 
average inpatient costs of patients using ORC vs. other hemostats (MCH, ROC, MPH) 
were 21,101 RMB (±21,390), 23,246 RMB (±15,545), respectively. There was a signifi-
chronic pulmonary disease. The sunitinib cohort had less time between diagnosis and 
index prescription than the pazopanib cohort (334 vs. 422 days; p= 0.037). Proportions 
of patients with treatment continuation, discontinuation, switching, or interruption 
were NS different. Before imputation, adjusted mean [SD] daily medication costs dur-
ing persistence were higher for sunitinib ($218.19 [34.73] vs. $177.07 [45.76]; p< 0.0001), 
but NS different after imputation (sunitinib $181.41 [22.34] vs. pazopanib $175.77 
[44.26]; p= 0.213). Twelve-month adjusted RCC-related medical costs were signifi-
cantly lower for sunitinib than pazopanib before imputation ($36,638.96 [$25,199.38] 
vs. $45,219.75 [$34,828.70], p= 0.021) and after imputation ($36.393.90 [$26,543.89] vs. 
$45,652.99 [$35,226.83], p= 0.015. The RCC-related prescription costs were NS different 
between the two drugs before and after imputation. CONCLUSIONS: Treatment pat-
terns and persistence with sunitinib or pazopanib were NS different. Sunitinib daily 
cost was NS different from pazopanib after imputation. Further analysis is needed 
regarding dosing schedule, days supply, and related calculations.
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OBJECTIVES: The study aimed to (1) develop a cost model for colonoscopy prepa-
ration among patients referred for colonoscopy using split-dose reduced-volume 
oral sulfate solution (OSS) and generic polyethylene glycol with electrolytes solu-
tion (PEG-ELS), (2) examine cost-savings associated with OSS versus PEG-ELS, 
and (3) assess the robustness of the cost model. METHODS: Clinical efficacy of 
each agent was based on the results of a 541-patient clinical trial comparing OSS 
to PEG-ELS. Cleansing agent and colonoscopy procedure costs were calculated 
from OptumHealth Reporting & Insights claims data for 2010–Q12013. In the cost 
model, patients’ colonoscopies were tracked until the patient reached age 75. The 
difference per patient per year (PPPY) in total cleansing agent and colonoscopy 
procedure costs over the time horizon between the OSS and PEG-ELS cohort was 
calculated. One-way sensitivity analyses were also conducted to test the robust-
ness of the cost model. RESULTS: The cost model showed that OSS patients had 
fewer colonoscopies over the time horizon (OSS: 0.158 vs. PEG-ELS: 0.170 PPPY). 
Total PPPY costs were $280.34 for the OSS cohort and $296.36 for the PEG-ELS 
cohort, resulting in a cost-saving of $16.01 to the payer for the OSS cohort. Varying 
the annual colonoscopy completion rate, surveillance intervals, time horizon, and 
proportion of high risk patients did not change the observation of cost-savings 
under OSS. Cost-savings switched from the OSS to the PEG-ELS cohort in three 
cases: (1) base-case cost of a completed colonoscopy decreased by 75%, (2) base-
case cost of OSS increased to over $143 per usage, and (3) all non-completers 
were lost to follow up. CONCLUSIONS: From a payer’s perspective, the cost model 
showed that the use of OSS as the cleansing agent resulted in potential cost-
savings compared with PEG-ELS. The cost model was robust and cost-savings 
under OSS remained under various sensitivity analyses.
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OBJECTIVES: Cancer-related morbidity and mortality have dramatic impacts on 
patients and society. Most studies on the economic burden of cancer have focused 
on the direct costs attributed to healthcare expenditures or the indirect costs due 
to premature mortality. Cancer’s impact on absenteeism has been less well studied. 
The objective of this review was to summarize and characterize the literature on the 
economic impact of cancer-related absenteeism. METHODS: We searched PubMed for 
articles related to the costs of cancer-related absenteeism, which we defined as any 
type of workplace absence. Additional eligibility criteria included the evaluation of 
costs per patient and the presentation of absenteeism endpoints in monetary terms. 
Studies were characterized according to cancer type, healthcare setting (U.S., EU, Asia), 
valuation approaches, study time period, absenteeism endpoints, and cost results. 
All costs were adjusted to 2013 dollars or Euros using consumer price indexes and 
exchange rate data. RESULTS: We found 16 articles that met our inclusion criteria. 
Seven cancer or pre-cancer types were studied, with breast cancer (7 studies) and 
colorectal cancer (3 studies) being the most common. Absenteeism endpoints used 
by study authors varied considerably and included terms such as “absenteeism” (the 
actual term), “sick leave,” “short-term disability,” and “permanent disability (reduced 
hours or workforce departure).” For U.S. studies, total annual absenteeism costs per 
patient ranged from $3,235 (precancerous cervical lesions) to $59,241 (colorectal 
cancer). For European studies, total mean absenteeism costs per patient based on 
time until retirement age of 65 ranged from € 54,216 (breast cancer) to € 129,977 (colo-
rectal cancer). Overall, colorectal cancer was associated with the highest absentee-
ism costs. CONCLUSIONS: Based on the literature, it is apparent that cancer-related 
absenteeism poses a significant economic burden to patients, employers, and society. 
Additional research is required to better understand the absenteeism costs of various 
types of cancer and to make more accurate comparisons between them.
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